Our Tests
Mdxhealth’s molecular diagnostic solutions address a significant unmet medical need for timely, actionable information that addresses the challenges of the current standard of care for diagnosing and treating prostate cancer. Our tests identify patients at increased risk for aggressive prostate cancer, aiding in the selection of at-risk men for prostate biopsy, as well as in the selection of newly-diagnosed men for appropriate treatment.
Post-Biopsy
A tissue test to improve the identification of men at risk for undetected clinically significant prostate cancer after a negative biopsy.
Localized Prostate Cancer
A genomic assay designed for men with low-, intermediate-, and high-risk localized prostate cancer to help guide treatment decisions at the time of diagnosis.
Pre-Biopsy
A highly predictive urine test to help identify men at risk for aggressive prostate cancer prior to initial biopsy.
Urinary Tract Infection (UTI)
An advanced UTI testing solution that quickly provides personalized therapy options.
Compare Our Tests
Compare |
Select mdx |
Confirm mdx |
GPS |
Resolve mdx |
|---|---|---|---|---|
|
Test Overview |
Prostate Cancer |
Prostate Cancer |
Prostate Cancer |
Urinary Tract Infection (UTI) |
|
Patient eligibility |
For patients being considered for a prostate biopsy (elevated PSA or suspicious DRE) |
Patients with cancer-negative biopsy results (benign, HGPIN, ASAP/atypia) within 30 months |
Patients diagnosed with NCCN very low- to high-risk prostate cancer within 36 months. |
For patients presenting with urinary tract infection symptoms. |
|
Technology |
RT-PCR genomic assay |
DNA RT-PCR methylation assay |
RT-PCR genomic assay |
RT-PCR & ASTX |
|
Genes |
HOXC6 and DLX1 |
GSTP1, APC, RASSF1a |
AZGP1, FAM13C, KLK2, SRD5A2, FLNC, GSN, GSTM2, TPM2, BGN, COL1A1, SFRP4, TPX2, ARF1, ATP5E, CLTC, GPS1, PGK1 |
-- |
|
Specimen type |
First void urine |
Prostate biopsy tissue cores |
Prostate biopsy tumor tissue |
Clean catch, mid-stream urine; catheter urine |
|
Turnaround time |
5 business days |
10 business days |
10 business days |
Within 48 hours from receipt at lab |
Science & Technology
Mdxhealth has a proprietary portfolio of biomarkers and bioinformatic technologies from which it develops and commercializes state-of-the-art diagnostic, prognostic and predictive tests for urologic oncology.
